GlassScriptPhysician profile
Sergei V Shumaster
NPI 1366830606
$5,316.16
in general payments reported to CMS, 2019-2025
41 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $104 · 2021: $314 · 2022: $567 · 2023: $1,034 · 2024: $1,149 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,376.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $870.77 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $520.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $517.81 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $451.33 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $416.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.25 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $389.94 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $226.31 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Astellas Pharma US INC | $197.59 | 2019-2025 | Veozah |
| Amgen INC. | $196.10 | 2019-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $145.05 | 2019-2025 | Rexulti |
| Exact Sciences Corporation | $128.61 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $65.67 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $47.60 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $47.08 | 2024-2025 | Zenpep |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergei Shumaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.